March 29th 2022
Is prolonged grief disorder an important addition to the DSM-5-TR?
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
BURST CME™: Taking ALS Management to the Next Level
View More
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
View More
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
10/13/2023
View More
5th Annual International Congress on the Future of Neurology®
09/22/2023-09/23/2023
View More
Medical Crossfire®: What Strategies Can the Care Team Implement to Optimize the Management of Pediatric Patients with NF1?
View More
PER® Postgame™: MS Meeting Updates – Integrating the Latest Data to Optimize Care in the COVID-19 Era
View More
Expert Illustrations & Commentaries™: A Family Physicians’ Guide to Migraine Treatment – Emerging Therapies and Evolving Paradigms
View More
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Collaborating Across the Continuum™ : Managing Relapsing MS – A Focus on the Utility of CD20-Targeted B-Cell Therapy
View More
Understanding Best Care Practices for Hemorrhagic Stroke – A Focus on the Role of DOAC Reversals
View More
2022 4th Annual International Congress on the Future of Neurology
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Addressing Healthcare Inequities in Stroke Care: How Can We Play an Active Role in Improving Outcomes for All Patients?
View More
Taking Pompe Disease Management to the Next Level: Optimizing Clinical Assessments and Treatment Decision-Making
View More
From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease
View More
From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease
View More
Shaping the Management of Multiple Sclerosis – The Potential for BTK Inhibitors in Clinical Practice
View More
Show Me Your Care Plan! Nursing Strategies to Support Continuity of Care in the Treatment of Multiple Sclerosis
View More
Advances In™ Personalizing MS Management Plans: Strategies for Optimizing Long-Term Patient Outcomes in MS and Individualizing Treatment within the S1P Receptor Modulator Class
View More
Virtual Tumor Board®: Multidisciplinary Approaches to Treating Cancer-related LEMS
View More
Medical Crossfire®: What Strategies Can the Care Team Implement to Optimize the Management of Pediatric Patients with NF1?
View More
Virtual Tumor Board®: Multidisciplinary Approaches to Treating Cancer-related LEMS
View More
2022 Annual Psychiatric Times™ World CME Conference™ - Day Three
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Does Research Support “Craving” as a Core Symptom of Substance Use Disorders in DSM-5?
January 11th 2011Recently, the Substance Use Disorder Work group of the DSM-5 announced the inclusion of “craving” in the diagnostic criteria for all substance use disorders despite its lack of empirical support from the very analyses conducted by that Workgroup. In addition, no detailed literature review supports the decision to make “craving” a core symptom of Substance Use Disorder syndromes.
Read More
A Letter to the Board of Trustees of the APA
December 18th 2010We are delighted that you have appointed a DSM-5 Scientific Review Work Group and charged it with assessing the quality of evidence supporting the DSM 5 proposals.This is great news, probably the last hope to weed out proposals that could do great harm to the Association, our field, and to our patients.
Read More
Adding the Diagnosis of Temper Dysregulation Disorder to DSM-5
December 1st 2010These issues-among others-raise this question: Is the addition of a new diagnosis such as TDD to DSM-5 the best way to manage the issue of classification of youths with chronic, severe irritability and potential misdiagnosis of bipolar disorder?
Read More
DSM5 Task Force: Do Not Go to the Mass Media-Do Your Homework
December 1st 2010As I was driving to work on February 10, 2010, I listened to the National Public Radio host Melissa Block talking about how children labeled “bipolar” may get a new diagnosis. I was shocked that the chair of one of the DSM5 work groups, David Shaffer, MD, would discuss a controversial diagnostic topic with the media.
Read More
The DSM-5 Field Trials (Part 2): Wrong Goals and Wrong Methods Make Them Irrelevant
November 25th 2010The ideal field test would study how the diagnostic manual will eventually perform under conditions most closely approximating its future everyday use. The goal is to avoid unpleasant surprises in translation from what has been written on paper to what is practiced in real life. No field test can ever approach the ideal.
Read More
DSM-5 Field Trials (Part 1)-Missed Deadlines Have Troubling Consequences
November 19th 2010Eventually, DSM-5 will be a rushed patch-work. The only hope for a usable DSM-5 is for the Trustees to exert their authority to correct an errant process. But they will act only if there is mounting outside pressure and widespread public concern.
Read More
Science Versus Pragmatism in the DSM: Finding A Middle Ground
November 18th 2010The DSM does and must involve both science and pragmatism. It must use the science that is available, but it must also make countless judgment calls that are not grounded in solid empirical evidence-and surely it makes sense to consider practical consequences in doing the latter.
Read More
AAPP Bulletin: Recent Issues Devoted to Conceptual Questions in DSM-5
November 4th 2010The project culminating in the 2 issues of the Bulletin of the Association for the Advancement of Philosophy and Psychiatry (the Bulletin) included in PDF format with this introduction has its own history.
Read More
DSM is a Many-Dimensioned Thing
October 19th 2010In a recent issue of Psychiatric News, members of the DSM-5 Task Force reported on the dimensional measures being considered for DSM-5. These take 2 forms: severity scales for individual disorders, and “cross-cutting” measures that cut across disorders. For this brief piece, I will focus on the latter, the more interesting and controversial of the proposed dimensions.
Read More
Grief and Depression: When Science and Terminology Get Confused
September 15th 2010In his ongoing critique of the DSM-5 process, Dr Allen Frances started a brushfire recently in challenging the DSM-5 Mood Disorders Work Group proposal to remove the bereavement exclusion from the diagnostic criteria for a major depressive episode. Here’s a summary of the debate.
Read More
The Meaning of Addiction: DSM-5 Gives the Lie to Addiction as a Chronic Brain Disease
August 25th 2010Although Charles O’Brien, MD, who heads the substance-related disorders work group, is a vigorous proponent of the notion of addiction as a disease, nothing about the proposed DSM-5 substance-related disorders section supports the idea that the syndrome is best understood as a chronic brain disease.
Read More
The Cultural Dimension in DSM-5: PTSD
August 15th 2010Any effort to develop a diagnostic manual for world-wide use must grapple with the question of cross-cultural applicability. The description and diagnostic criteria for schizophrenia must work as well in East Timor as in the US or France. In this piece I choose PTSD to show the complexity of the cultural issue for DSM-5.
Read More
Early Alzheimer's Diagnosis and Treatment: Future Hopes, Current Dangers
August 7th 2010The furor surrounding the recently proposed Alzheimer's Guidelines was provoked by their premature attempt to introduce early diagnosis, well before accurate tools are available. The same laudable, but currently clearly unrealistic ambition has propelled two of the worst suggestions for new diagnoses in DSM-5: Psychosis Risk and Mild Neurocognitive.
Read More
Response to: “Psychiatric Symptoms Can be Understood Even When These Symptoms Cannot Be Explained”
July 16th 2010Dr Muller, in his piece “Psychiatric Symptoms Can be Understood Even When These Symptoms Cannot Be Explained,” makes a number of assertions about DSM-III and its successors that reflect a mischaracterization of its “descriptive approach.”
Read More
DSM-5: Continuing the Confusion about Aging, Alzheimer’s and Dementia
July 15th 2010Since the early twentieth century, when Alois Alzheimer and Emil Kraepelin constructed it as a unified clinical-pathological entity, Alzheimer’s disease has been both one of the most stable and one of the most problematic neuropsychiatric entities.
Read More